Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-M07D1 |
| Synonyms | |
| Therapy Description |
BL-M07D1 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeted monoclonal antibody trastuzumab linked to a topoisomerase I inhibitor (Ed-04), which potentially induces cell cycle arrest and apoptosis and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2643). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-M07D1 | BLM07D1|BL M07D1 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | BL-M07D1 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeted monoclonal antibody trastuzumab linked to a topoisomerase I inhibitor (Ed-04), which potentially induces cell cycle arrest and apoptosis and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2643). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06293898 | Phase I | BL-M07D1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Recruiting | USA | 0 |